a

Publication	
Eslam M (2020) [a]	A new definition for metabolic dysfunction–associated fatty liver disease: an international expert cons
Eslam M (2020) [b]	MAFLD: a consensus–driven proposed nomenclature for metabolic associated fatty liver disease
Eslam M (2020) [c]	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis a
Lin S (2020)	Comparison of MAFLD and NAFLD diagnostic criteria in real world
Stefan N (2021)	Global pandemics interconnected – obesity, impaired metabolic health and COVID–19
Zheng KI (2020)	Obesity as a risk factor for greater severity of COVID–19 in patients with metabolic associated fatty li
Yamamura S (2020)	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Younossi ZM (2021)	From NAFLD to MAFLD: implications of a premature change in terminology
Remmerie A (2020)	Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the
Lee H (2021)	Metabolic dysfunction–associated fatty liver disease and incident cardiovascular disease risk: a natio
Fouad Y (2020)	What's in a name? Renaming 'NAFLD' to 'MAFLD'
Kim D (2021)	Metabolic dysfunction–associated fatty liver disease is associated with increased all–cause mortality
Tilg H (2020)	From NAFLD to MAFLD: when pathophysiology succeeds
Sun DQ (2021)	MAFLD and risk of CKD
Targher G (2020)	Risk of severe illness from COVID–19 in patients with metabolic dysfunction–associated fatty liver di

Citation count: 0, 500, 1000, 1500, 2000

b

Publication	
Eslam M (2020) [a]	A new definition for metabolic dysfunction–associated fatty liver disease: an international expert cons
Eslam M (2020) [b]	MAFLD: a consensus–driven proposed nomenclature for metabolic associated fatty liver disease
Eslam M (2020) [c]	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis a
Lin S (2020)	Comparison of MAFLD and NAFLD diagnostic criteria in real world
Stefan N (2021)	Global pandemics interconnected – obesity, impaired metabolic health and COVID–19
Yamamura S (2020)	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Zheng KI (2020)	Obesity as a risk factor for greater severity of COVID–19 in patients with metabolic associated fatty li
Younossi ZM (2021)	From NAFLD to MAFLD: implications of a premature change in terminology
Remmerie A (2020)	Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the
Lee H (2021)	Metabolic dysfunction–associated fatty liver disease and incident cardiovascular disease risk: a natio
Fouad Y (2020)	What's in a name? Renaming 'NAFLD' to 'MAFLD'
Kim D (2021)	Metabolic dysfunction–associated fatty liver disease is associated with increased all–cause mortality
Sun DQ (2021)	MAFLD and risk of CKD
Tilg H (2020)	From NAFLD to MAFLD: when pathophysiology succeeds
Shiha G (2021)	Redefining fatty liver disease: an international patient perspective

Citation count: 0, 500, 1000, 1500, 2000

Fig. S2 a, b Highly cited MAFLD papers in Scopus (**a**) and Web of Science (**b**).